Conversion surgery for tislelizumab combined chemotherapy for T4a/N3 esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II study.

Chen Zhang, Hongjing Jiang, Jie Yue et al.|Journal of Clinical Oncology|2024

Cited by 0